Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now

Broader equities have been relatively volatile over the past few months. In an environment like this, it's best to prioritize investing in well-established, profitable corporations. While small-cap stocks may have higher upside potential than much larger companies, the risks they entail often make them not worth investing in.With that as a backdrop, let's consider one smaller company that has performed pretty well over the trailing-12-month period, but isn't worth your time: Amarin (NASDAQ: AMRN). Instead of betting on this small drugmaker, it's best to put your hard-earned money into a pharmaceutical leader like Novartis (NYSE: NVS) instead.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool